The Discounted Cash Flow (DCF) valuation of Nektar Therapeutics (NKTR) is (97.27) USD. With the latest stock price at 49.89 USD, the upside of Nektar Therapeutics based on DCF is -295.0%.
Based on the latest price of 49.89 USD and our DCF valuation, Nektar Therapeutics (NKTR) is a sell. selling NKTR stocks now will result in a potential gain of 295.0%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 5.9% - 8.6% | 7.3% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (344.16) - (57.59) | (97.27) |
| Upside | -789.8% - -215.4% | -295.0% |